How JDRF is working to ease Brexit transition for people with type 1 Diabetes
The Juvenile Diabetes Research Foundation -JDRF- is working hard to ease the transition for patients managing type 1 diabetes with the chief concern being the accessibility to insulin and other healthcare facilities and drugs. The charity is working together with the Department of Health and Social care to mitigate the risks associated this transition for type one diabetics. An official statement by JDRF says that the needs of patients with type 1 diabetes is the priority.
What happens when the UK leaves EU?
Synthetic human insulin, which happens to be the main drug relied upon by type 1 diabetes patients is imported to the UK from three main pharmaceutical companies –Sanofis, Novo Nordisk and Eli Lilly. The question now remains what would happen if the Brexit deal fails and the UK leaves the EU? Would insulin supplies stop? If this happens what would be the fate of the large population who depend on these insulin supplements for survival?
The natural reaction to this has been for people managing diabetes, pharmacies and healthcare professionals to think of getting a stockpile of insulin “for the rainy days”, but the government has sued for calm and has also made requests for the manufacturers of the drugs to ensure that there’s at least a six-week’ supply of insulin for easy access. This also prompted a response from the three main suppliers who have communicated their desire to stockpile reserves of up to 16 weeks.
Importing insulin and other drugs after the EU exit is quite a necessity, as according to B. Turner, “insulin is not an alternative extra for people with diabetes who rely on it”. She further “encouraged the companies manufacturing insulin, and those involved in bringing it into the country to work together to ensure an uninterrupted supply”
For type 1 diabetes patient, the dependence on insulin cannot be negotiated and thus it is very necessary for its provision to people who need it. Any loss or cut in supply of insulin to this category of citizens could prove very dangerous and fatal.
JDRF understands this, hence the reason why JDRF officials have been in constant touch with government officials, the Department of Health and Social care and other relevant bodies to find ways to keep the insulin supply steady.
When the Brexit finally comes through, the efforts of JDRF will hopefully yield immense benefits for people dependent on insulin.
Aaron Kowalski, Ph.D., Chief Mission Officer of the JDRF reiterate D the charity’s commitment to ensuring that insulin is available to people managing type 1 diabetes at a low, predictable out-of-pocket cost, and also have access to the insulin's that work best for them. One way they are doing this is by urging insulin manufacturers to improve the current flow of payment and product supplies to their destinations.
JDRF continues to raise awareness for the needs and concerns around insulin availability in the event that the UK exits the EU, and will continue to give updates concerning this.